Director Yang first introduced the high and new technology industry policy of tianjin, especially the supporting policy in the field of biomedicine.

In 2011, the company was named as the municipal "recombinant protein drug engineering research center" in the innovation foundation project and special project of chongqing development and reform commission, which further improved and expanded the technical advantages of the platform.

The construction of this technology platform will more vigorously promote the company's advantages in biotechnology drug development, especially in the pilot scale process amplification.

Biological products my company a class of new drugs to recombinant human parathyroid hormone (1-84) completed 鈪� phase clinical studies. The results showed that the drug safety was good and in line